semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic for Parkinson's disease. 2. Positive [¹²³I]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal degeneration 3. Diagnosed within one year from enrolment 4. Hoehn and Yahr score <= 2 at enrolment 5. Optimal symptomatic therapy, not requiring adjustments, for at least 3 months  Dementia or other neurological disorder at baseline visit 2. Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit 3. Prior use of dopaminergic treatment
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Parkinson Disease Parkinson's disease Stable on levodopa therapy with fluctuations  Chronic gastrointestinal disease Recent antibiotic or probiotic therapy Pregnant Immunocompromised
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Parkinson Disease Males and females over age 50 Meet for typical idiopathic PD Hoehn & Yahr stage I-III Treated with levodopa/carbidopa Have PD with Mild Cognitive Impairment (PD-MCI) according to Movement Disorders Society (MDS) Level II diagnostic criteria Medications should be stable for 4 weeks prior with no changes planned during the study (we will document any unplanned changes)  Dementia according to MDS or MoCA score <21 Other neurological disorders Brain surgery History of psychotic disorder Change in medication during the study Treatment with medications that interfere with cognition (e.g. anticholinergics) Any condition that would interfere with participation (e.g., non-English speaking, significant current depression)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cirrhosis Hepatic Encephalopathy Minimal Hepatic Encephalopathy Covert Hepatic Encephalopathy Age >18 years 2. Cirrhosis defined by any one of the following 1. Cirrhosis on liver biopsy or transient wave elastography 2. Nodular liver on imaging 3. Endoscopic or radiological evidence of varices in a patient with chronic liver disease 4. Platelet count <150,000/mm3 and AST/ALT ratio >1 in a patient with chronic liver disease 5. Patients with frank decompensation (ascites, HE, variceal bleeding, hepato-pulmonary syndrome) 3. Prior HE controlled on standard of care therapy defined as lactulose or rifaximin for at least 2 months prior to enrollment. 4. Serum albumin <4 gm/dl 5. Cognitive impairment on any of the three testing strategies for HE including Psychometric hepatic encephalopathy score (PHES), Stroop test and Critical Flicker Frequency 1. PHES aggregate score <-4SD based on norms published in Allampati et al located at the website www.encephalapp.com 2. Stroop OffTime+OnTime values greater than norms published in Allampati et al located at the website www.encephalapp.com 3. Critical Flicker Frequency value <39 Hz  Unclear diagnosis of cirrhosis (does not meet the outlined above) 2. No prior overt HEepisodes 3. HE uncontrolled on standard of care defined as a mini-mental status exam<25 4. On regular IV albumin infusions due to scheduled paracentesis within the last 3 months 5. Recent alcohol abuse (within 3 months) 6. Unable to give consent 7. Current or recent invasive bacterial or fungal infections (<1 month) 8. Allergic reactions to IV albumin 9. Current or recent congestive heart failure (Systolic ejection fraction <25%) within the last year 10. Pregnancy (positive urine pregnancy test at screening) 11. In the opinion of the PI, those who are unlikely to survive 6 weeks or be able to adhere to the trial activities
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Parkinson Disease at least 40 years of age neurologist-diagnosed Parkinson's Disease Hoehn & Yahr (H&Y) stages 1 to 4 were able to walk 10 m with or without aids  visual, auditory, and orientational problems affecting study results orthopedic problems affecting walking other neurologic conditions, cardiovascular, musculuskeletal, and vestibular disease
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Parkinson Disease Diagnosis of idiopathic Parkinson's and Hoehn and Yahr score of 2.5 or more; Willing to participate and refrain from driving whist taking zolpidem/placebo; Within age range 40 to 80 years  Any contraindications as stated in Summary of Product Characteristics (SmPC) for zolpidem:- Hypersensitivity to zolpidem tartrate; Obstructive sleep apnoea; Myasthenia gravis; Severe hepatic insufficiency; Acute and/or severe respiratory depression; Psychotic illness. and in addition Unable or unwilling to give informed consent ; Current therapy with central nervous system (CNS) depressants; Current therapy with Cytochrome P450 (CPY450) inhibitors or inducers (specifically CYP3A4); Pregnancy and breast feeding women; History of alcohol or substance abuse; Employed in a role that involves driving or operating heavy machinery; Participation in another interventional clinical trial
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 60.0-75.0,  Parkinson Disease Able to provide informed consent. 2. A clinical diagnosis of idiopathic PD. 3. A stable and optimal medical regimen of anti-parkinsonian drug therapy for the duration of the study. 4. Modified Hoehn and Yahr stage between 1.0 and 3.0 in the OFF state. 5. Right-hand dominant and primarily right-side affected to prevent confounds due to handedness and affected side  An uncontrolled medical condition (i.e. hypertension, diabetes, etc). 2. Evidence of secondary or atypical parkinsonism as suggested by: 1. History of CVA's, exposure to toxins, neuroleptics or encephalitis. 2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy or significant orthostatic hypertension. 3. Metal in the skull or the eye, such as a cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain, cochlear implants, and metal fragments in the eye, as these may make TMS and tDCS unsafe. 4. An uncertainty about the presence of metal objects in a subject's body exists. 5. Hearing loss, have had a brain tumor, a stroke, head trauma, epilepsy or a history of seizures, have another neurological disorder other than a movement disorder, or have a head injury where they passed out for more than a few seconds. 6. Pregnant or thought to be pregnant. 7. Irrepressible dyskinesia or tremor to prevent the confound of excessive EMG during TMS testing at rest. 8. Any other neurological disorders. 9. Meeting of any of the TMS given in international guidelines
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Multiple Sclerosis diagnosed with MS based on McDonald  any neurological condition other than MS
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Parkinson Disease The primary for diagnosis are idiopathic Parkinson's disease, defined as bradykinesia with resting tremor or muscular rigidity according to MDS-PD diagnosis (2015). The examination of major symptoms needs to be performed by the methods described in the Unified Parkinson's Disease Rating Scale (UPDRS)  Definite cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar eye movement abnormalities (such as sustained staring induced nystagmus, giant square wave beats, and distant hypertonia) Downward vertical suprachiasmatic gaze palsy, or selective downward vertical scanning is slowing down Within five years of onset, the disease was diagnosed as a likely frontotemporal dementia or primary progressive aphasia (according to revised diagnostic for frontotemporal dementia published in 2011) With more than three years after the onset of the disease, Parkinson's disease symptoms are still limited to the lower limbs They have been treated with dopamine receptor blockers or dopamine depletion agents and the dosage and duration of administration are consistent with the diagnosis of drug-induced Parkinson's disease Although the condition is at least moderately severe, there is no discernible effect on high-dose levodopa therapy Definite cortical hypoesthesia (such as loss of skin writing and body recognition when the primary sensory function pattern is complete), definite motor aphasia of body concept, or progressive aphasia Functional neuroimaging study of the presynaptic dopaminergic system shows normal results There is evidence of Parkinson's disease or other diseases suspected to be related to the patient's symptoms, or professional physicians identify they may be other syndromes rather than Parkinson's disease based on a complete diagnostic assessment
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 21.0-99.0,  Parkinson Disease Individuals with a diagnosis of Parkinson's Disease (made by movement disorders specialist) will be included in this study. Additional self-reported ability to walk ~6 minutes overground as well as walk on a treadmill for a total of 10 minutes with rest breaks as needed, and be classified as Stage 2, or 3 on the Hoehn and Yahr Scale (Goetz et. al, 2004)  Hoehn and Yahr Stages 1, 4, or 5, uncontrolled cardiorespiratory/metabolic disease (e.g., cardiac arrhythmia, uncontrolled hypertension or diabetes, orthostatic hypertension, chronic emphysema), or other neurological or orthopedic disorders that may affect walking. The investigators will also participants with severe communication impairments, which could impede understanding of the purpose or procedures of the study or an inability to comply with experimental procedures
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Functional Movement Disorder Patients with a clinical diagnosis of Functional Movement Disorder (e.g. functional tremor, functional dystonia, functional myoclonus) based on Fahn-Williams or OrgMD (e.g. Parkinson disease, essential tremor, cervical dystonia) evaluated by a fellowship-trained movement disorder neurologist at Cleveland Clinic 2. Patients with mild to severe involuntary movement as a result of the movement disorder, visible for video-recording  Significant cognitive impairment that prevents proper informed consent 2. Patients whose movement disorders cannot be captured on video
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease Essential Tremor Dystonia Must be previously treated with or eligible for implantation with a deep brain stimulation system
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease Diagnosis of classic PD with history of clinically meaningful response to levodopa Disease duration >15 years since diagnosis Hoehn & Yahr stage >IV "on" or "off" levodopa Consent signed by subject, if possible If subject is cognitively impaired, consent signed by power of attorney or legally authorized subject representative Assent from the study subject, if possible Stable dose of all medications for 60 days prior to Day 1 of first week of study  Atypical parkinsonian syndrome (e.g., never responded to levodopa, and/or atypical signs) Acute or unstable medical condition such as heart disease, kidney and liver failure History of HIV, hepatitis B and C Use of moderate to strong CYP 3A4 modulators (see both inhibitors and inducers in Appendix BB)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Idiopathic Parkinson's Disease Right-handedness (as assessed by the Edinburgh Handedness Inventory) 2. Being in stable treatment with the administration of L-dopa and dopamine agonists (i.e. not having motor fluctuations and/or dyskinesia) 3. Having a Hoehn & Yahr score between 1.5 and 3  Presence of severe sensory deficits 2. Presence of overt signs of dementia (a. mini-mental state examination, MMSE must be ≥24; b. intelligence quotient ≥75). 3. Comorbidity with other psychiatric disorders that might interfere with task execution (i.e. attentional disorders). 4. Presence of severe tremor or rigidity of the right arm in the OFF medication state
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vascular Diseases Carotid Artery Diseases Aneurysmal Disease Peripheral Artery Disease All patients attending for aortic aneurysm repair, carotid artery surgery and lower limb revascularisation under the care of the Vascular Surgery team 2. Willing and able to give informed written consent  Those unable to give informed written consent 2. Those <18 years of age 3. In the opinion of the investigator unable or unwilling to comply with the requirements of the study